Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: FNS who wrote (581)	3/20/1998 7:12:00 PM
From: Eman03	Read Replies (3) \| Respond to of 965

Something for all to think about related to the lawsuit and the purchase in general. Follow the chain here: 1. Roche purchased Boheringer Mannheim 2. Centocor bought Retavase from Roche for ~$330 million 3. Retavase has approximately 20% of the market, Activase has the other 80%. 4. Activase is owned by Genentech 5. Roche owns upwards of 60% of Genentech So to sum it all up, Roche is flush with ~$330 million in new cash, is a generally nasty company, and is looking to bury Centocor now that they have the competitive product. Roche could have eliminated the lawsuit as part of the negotiation because of their level of owership in Genentech, but they didn't. They are actually using Genentech to put on the heat, and this won't be all of it. There will be price competition, and there will be a strong marketing push on the part of Roche. Life will not be easy for Centocor.